The Brazilian Health Ministry has refused to add the medication finerenone to the Unified Health System (SUS), a decision that affects patients with chronic kidney disease related to type 2 diabetes. This refusal was confirmed through a dispatch published in the Official Gazette, where the ministry denied a reconsideration request from the pharmaceutical company Bayer. The decision underscores the ministry's responsibility, particularly through the health technology assessment department, which evaluates and determines the incorporation of new medicines into the public health system.

The refusal is tied to process number 25000.048005/2025-19, which reflects a decision made on December 26, 2025, not to incorporate finerenone. This indicates a continuity in the ministry's stance regarding the medication. Following the technical decision, the process will now be forwarded for final evaluation by the Minister of Health, as the regulation stipulates for the incorporation of new health technologies.

Finerenone is recognized for its potential benefits in protecting kidneys, particularly for diabetic patients, and its non-approval for SUS raises concerns regarding access to innovative treatments within the public health system. The decision could have significant implications for diabetes management in Brazil, potentially limiting treatment options available to patients suffering from related kidney conditions.